Posted by Michael Wonder on 19 Jul 2018
Lilly's once-weekly Trulicity (dulaglutide) label updated to include data showing benefits for adults with type 2 diabetes and chronic kidney disease
19 July 2018 - The U.S. label for Eli Lilly's once-weekly Trulicity (dulaglutide) is updated to show the medicine's safety and efficacy in people with type 2 diabetes who have moderate to severe chronic kidney disease.
The label now includes data from the AWARD-7 clinical trial, which showed that people treated with Trulicity 1.5 mg or 0.75 mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss, compared to those treated with traditional basal-bolus insulin.
Trulicity is a once-weekly glucagon-like peptide-1 receptor agonist injectable prescription medicine to improve blood sugar (glucose) in adults with type 2 diabetes. It should be used along with diet and exercise.
